PropThink: Sizing Up Elagolix – A Blockbuster Drug

PropThink: Sizing Up Elagolix – A Blockbuster Drug

[ACN Newswire] – By Jason Napodano, CFAIn June 2012, Abbott Labs (NYSE:ABT) initiated a phase III clinical trial with elagolix to evaluate the safety and efficacy of the drug in female patients with endometriosis. Below … more

View todays social media effects on NBIX

View the latest stocks trending across Twitter. Click to view dashboard

Share this post